Following on the Precision Medicine Initiative (PMI) Summit hosted by the White House on February 25th 2016 (full video here), the Food and Drug Administration (FDA) organized a public workshop titled “Patient and Medical Professional Perspectives on the Return of Genetic Test Results.” The goal was to understand patient and provider perspectives on receiving genetic test results. The topic(s) discussed focused on better defining the specific information patients and providers prefer to receive, how those results should be returned, and what information is needed to understand the results so that they may effectively aid in medical decision-making. The presentation slides at the public workshop are available here along with the five case studies. FDA is requesting comments from the public till March 31st 2016. Comments from all stakeholders, including scientists, clinicians, care providers, patients and caregivers are posted here. PGRN would like to encourage pharmacogenomics researchers to post comments either as a group or individual. Let’s get the ball rolling and be a key player in genetic testing!
A symposium organized by the Pharmacogenomics Research Network (PGRN)
The field of pharmacogenomics has received considerable attention recently, since President Obama announced the Precision Medicine Initiative earlier this year. Complementing this effort, NIGMS launched a new version of the Pharmacogenomics Research Network (PGRN), which plans to become a focus for pharmacogenomics research in the U.S. and internationally, bringing together scientists and clinicians in diverse fields and across multiple sectors, including clinical pharmacologists in academia, industry and at the FDA.
The Hub team